Biopharmaceutical company Specialised Therapeutics announced on Sunday that the Thailand Food and Drug Administration has approved YONDELIS (trabectedin) for the treatment of adult patients with advanced soft tissue sarcoma (STS).
This approval grants access to YONDELIS for patients who have failed prior treatment with anthracyclines and ifosfamide, or for those who are unsuited to receive these agents.
The decision was based on clinical efficacy and safety data from a Phase 3, randomised, open-label, controlled study that evaluated YONDELIS versus chemotherapy agent dacarbazine in patients with unresectable or metastatic liposarcoma or leiomyosarcoma previously treated with an anthracycline and at least one additional chemotherapy regimen. In the pivotal Phase 3 clinical trial, patients treated with YONDELIS achieved a statistically significant improvement in median progression-free survival (PFS) of 4.2 months versus 1.5 months for trabectedin vs dacarbazine, representing a 45% reduction in the risk of disease progression or death.
According to Specialised Therapeutics, YONDELIS demonstrated a manageable safety profile, with severe (Grade 3 or 4) adverse reactions occurring in less than one-third of patients. The most common adverse reactions of any severity grade included neutropenia, nausea, vomiting, elevated liver enzymes (AST/ALT), anaemia, fatigue, thrombocytopenia, decreased appetite, and diarrhoea.
YONDELIS is an established antineoplastic agent originally derived from the sea squirt (Ecteinascidia turbinata). It exerts the anti-tumour effect by binding to the minor groove of DNA, disrupting the cell cycle and preventing cancer cells from multiplying.
Under an exclusive licensing agreement with global partner PharmaMar S.A., Specialised Therapeutics will be responsible for all regulatory, commercialisation, distribution, and medical engagement operations for YONDELIS in Thailand.
Breakthrough T1D and Walgreens Foundation join forces to support the type 1 diabetes community
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177
Traws Pharma reports final Phase 2a COVID-19 data and advances influenza programme
Shanton Pharma's SAP-001 receives EMA and FDA paediatric study waivers in hyperuricaemia
Ascletis announces submission of US IND application for oral obesity combination therapy
AstraZeneca acquires biotechnology company Omniose to strengthen vaccine capabilities
Medivir secures US patent protection for fostrox and lenvatinib combination until 2044
PharmaLogic to acquire CDMO business and manufacturing facility from Lantheus
Ribo submits European Clinical Trial Application for SR122 in mixed and severe dyslipidaemia
Spermosens and Genea agree IVF study of JUNO-Checked in Australia